Total Health
Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.
For more info visit our website at Total Health.
Las Vegas
Total Health
2020 ASCO Update on Recurrent Ovarian Cancer: Does Secondary Cytoreductive Surgery Impact Patients Favorably?
FEATURING
Carolyn Muller
- 24 views
- October 13, 2020
Total Health
2020 ASCO Update on Platinum Sensitive, Relapsed Ovarian Cancer: Is There an OS Benefit With Maintenance PARPi?
FEATURING
Carolyn Muller
- 348 views
- October 13, 2020
- 3
Total Health
PARPi Efficacy in Recurrent Platinum Sensitive Ovarian Cancer: Is Olaparib More Effective as Mono or Combination Therapy?
FEATURING
Carolyn Muller
- 128 views
- October 13, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on R/R AML: Is AMG 330 Safe and Tolerable?
FEATURING
Michael Deininger
- 115 views
- October 12, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Response in CP Disease?
FEATURING
Michael Deininger
- 363 views
- October 12, 2020
- 3
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on PSMA in Prostate Cancer: Is 18F-DCFPyL PET/CT Superior to Standard Imaging?
FEATURING
Nicholas Vogelzang
- 16 views
- September 30, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on IO in Advanced NSCLC: Nivo/Ipi + 2 Cycles of Chemo vs. 4 Cycles of Chemo - Did OS Improve?
FEATURING
Shayma Kazmi
- 102 views
- September 22, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstrate Favorable Clinical Activity?
FEATURING
Shayma Kazmi
- 401 views
- September 22, 2020
- 2
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Pembro vs. Chemo in 1L dMMR / MSI-H mCRC: Did Results of KEYNOTE-177 Confirm a New SoC?
FEATURING
Richard Kim
- 404 views
- August 13, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on mCRC: Can 3L T-DXd Be Effective in HER2+ Disease?
FEATURING
Richard Kim
- 306 views
- August 20, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest on Osimertinib in EGFR+ Disease?
FEATURING
Sandip Patel
- 170 views
- August 24, 2020
- 1